Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …

Antibody‐dependent cellular cytotoxicity (ADCC) is a set of mechanisms that target cells
coated with IgG antibodies of the proper subclasses (IgG1 in the human) to be the prey of …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are
characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …

Accumulating evidence suggests that the tumor microenvironment (TME) is involved in
disease progression and drug resistance in B cell malignancies, by supporting tumor growth …

ABSTRACT A prospective analysis of natural killer (NK) cell phenotype and function was
performed on fresh peripheral blood samples from untreated patients with B-cell chronic …

Introduction: Lenalidomide is an immunomodulatory drug (IMiD) with a unique mode of
action (MOA) that may vary across disease-type. It is currently approved in multiple myeloma …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially
different manifestations of the same disease that are similarly managed. A number of …

Simple Summary Patients with chronic lymphocytic leukemia who develop Richter's
Syndrome have a poor prognosis. Traditional chemo-immunotherapy approaches yield poor …

The introduction of BTK inhibitors and BCL2 antagonists to the treatment of chronic
lymphocytic leukemia (CLL) has revolutionized therapy and improved patient outcomes …

Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL)
include the addition of targeted therapies. The combination of lenalidomide and rituximab …